WILL HE BE WEARING CHILDREN'S CLOTHES WHEN HE'S A GROWN-UP?

Somatonorm® (somatrem) is successfully changing the outlook for this child and thousands like him suffering from short stature caused by growth hormone deficiency (GHD).

With early diagnosis and treatment, GHD children can achieve a normal adult height.

For the past two decades, KabiVitrum has pioneered growth hormone research.

The introduction of Somatonorm ensures that, for the first time, sufficient growth hormone is available to treat all GHD children.

Prescribing Information

Presentation A vial of sterile lyophilised powder of somatrem corresponding to 4IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2ml ampoule of water for injections for use in the reconstitution of the injection.

Uses The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

Dosage and Administration Route of administration: By intramuscular injection. Recommended dosage: The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular injections

Contra-indications, warnings, etc. Only patients with unfused epiphyses should be treated. Diabetes mellitus. Precautions: Patients treated with Somatonorm should be regularly assessed by a specialist in child growth. Side-effects: Clinical experience with Somatonorm is limited and recipients may develop antibody to growth hormone and E. coli protein. However, as with pituitary derived hormone, only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

Package Quantities Combined package containing one vial of somatrem 4 IU and one ampoule of 2ml water for injections

Price NHS Price £28.

Further Information Somatrem is the British Approved Name for methionyl human somatotropin.

Product Licence Number 0022/0060

KabiVitrum Limited, KabiVitrum House, Riverside Way, Uxbridge, Middx UB8 2YF.

Product Authorisation Number 187/28/1.

Eire KabiVitrum, Cahill May Roberts Ltd, P.O. Box 1090, Chapelizod, Dublin 20.

GROWTH SERVICE
KABIVITRUM

HE WANTS TO GROW. KabiVitrum CAN HELP HIM.

KV628 11/86

Indications Epilepsy (generalised tonic-clonic and partial seizures).
Dosage in epilepsy Use a gradually increasing dosage scheme, adjusting to patient's needs. Adults: 100-200mg once or twice daily, increasing slowly up to 800-1,200mg daily; in some cases 1,600mg daily may be necessary. Children: up to 1 year old, 100-200mg daily: aged 1-5 years, 200-400mg daily; aged 5-10 years, 400-600mg daily; aged 10-15 years, 600-1,000mg daily. It may be helpful to monitor drug levels: optimum therapeutic range is 3-10μg/ml (13-42μmols/l).
Side-effects Dizziness and diplopia (usually dose-dependent), less frequently dry mouth, diarrhoea, nausea and vomiting. Generalised erythematous rash, disappearing on cessation of therapy. Isolated reports of oedema, hyponatraemia, exfoliative dermatitis, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, cholestatic jaundice and acute renal failure. Blood count should be checked in early stages of treatment.
Precautions Caution in patients taking oral anticoagulants or requiring oral contraception. In pregnancy, potential benefits of Tegretol must be weighed against potential hazards. Do not administer with, or within two weeks of cessation of, MAOI therapy. Macrolide antibiotics (eg erythromycin) and isoniazid may elevate carbamazepine levels. In rats treated with carbamazepine for two years, incidence of liver tumours increased (no evidence of significant bearing on the therapeutic use of the drug). Serum folic acid levels should be observed during anticonvulsant therapy.
Contra-indications Previous drug sensitivity to Tegretol. Do not administer to patients with atrioventricular conduction abnormalities unless paced.
Packs Tablets of 100mg (PL0001/5027) basic NHS price £3.10 per 100, £14.93 per 500; tablets of 200mg (PL0001/5028) £5.76 per 100, £27.75 per 500; tablets of 400mg (PL0001/0088) £11.32 per 100. liquid 100mg/5ml (PL0001/0050) £5.53 per 300ml bottle.
* denotes registered trademark. Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.

Geigy

Tegretol®
carbamazepine BP

for the effective control of epilepsy

TG1

Epilim®
Sodium Valproate

In a wide range of epilepsies

Presentation 1. Epilim 200 Enteric Coated. A lilac-coloured, enteric coated tablet containing 200mg Sodium Valproate B.P. 2. Epilim 500 Enteric Coated. A lilac-coloured, enteric coated tablet containing 500mg Sodium Valproate B.P. 3. Epilim 100mg crushable tablets. A white, scored tablet containing 100mg Sodium Valproate B.P. 4. Epilim Syrup. A red, cherry-flavoured syrup containing 200mg Sodium Valproate B.P. per 5ml. 5. Epilim Liquid. A red, cherry-flavoured, sugar-free liquid containing 200mg Sodium Valproate B.P. per 5ml. **Indications** In the treatment of generalised, partial or other epilepsies. In women of child-bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and Administration** To be taken with or after food. Epilim may be given twice daily. Enteric coated tablets should be swallowed whole. **Monotherapy** *Adults:* Start at 600mg daily increasing by 200mg at 3 day intervals until control is achieved. (Maximum dose 2,500mg per day.) *Children over 20kg:* Initially 400mg/day with spaced increases until control is achieved. (Usually within the range 20-30mg/kg body weight per day.) *Children under 20kg:* 20mg/kg of body weight per day: in severe cases may be increased up to 40mg/kg/day. Increases above this only if plasma valproic acid levels, clinical chemistry and haematological parameters can be monitored. **Combined Therapy** It may be necessary to raise the dose when used with anticonvulsants which induce liver enzyme activity. Dosage of barbiturates should be reduced if sedation is observed. Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. **Contra-indications, Warnings** *Contra-indication:* Active liver disease. *Side effects:* Liver dysfunction including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. Patients most at risk are children under the age of three and those with congenital metabolic disorders, organic brain disease or severe seizure disorders associated with mental retardation. The incidents mainly occurred during the first 6 months of therapy and usually involved multiple anticonvulsant therapy. Clinical symptoms are more helpful than laboratory investigations in the early stages of hepatic failure. The onset of an acute illness, especially within the first 6 months, which may include symptoms of vomiting, lethargy or weakness, drowsiness, anorexia, jaundice or loss of seizure control is an indication for immediate withdrawal of the drug. Evidence to date does not establish which investigation could predict this possible adverse effect; measurement of liver function should be performed in the first 6 months of therapy in those who seem most at risk and those with a prior history of liver disease. Hyperammonaemia without hepatic damage can occur, it is usually transient, but may occasionally present clinically. If so Epilim should be discontinued. Valproic acid inhibits platelet aggregation. Thrombocytopenia has been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication. Pancreatitis, tremor, weight gain, transient hair loss, increased alertness, aggressiveness, hyperactivity, amenorrhoea, stupor and oedema have been reported. **Drug Interactions** Epilim may potentiate monoamine oxidase inhibitors and other antidepressants. Loss of efficacy of oral contraceptive agents does not appear to be a problem. **Women of Childbearing Age** Valproic acid and sodium valproate, like certain other anticonvulsants, have been shown to be teratogenic in animals. In women of childbearing age the benefits of these compounds should be weighed against the possible hazard suggested by these findings and their pregnancies should be carefully monitored. **Product Licence Numbers** Epilim 200 Enteric Coated 0623/0006. Epilim 500 Enteric Coated 0623/0005. Epilim 100mg crushable tablets 0623/0015. Epilim Syrup 0623/0004. Epilim Liquid 0623/0016. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.59. Epilim 500 Enteric Coated 100 tablets, £16.45. Epilim 100mg crushable tablets 100 tablets, £3.99. Epilim Syrup 200ml, £4.03. Epilim Liquid 200ml, £4.03. Further information is available from: Labaz: Sanofi UK Ltd., Floats Rd., Wythenshawe, Manchester M23 9NF. Tel: 061-945 4161.

Epilim
Sodium Valproate

helps to maintain the normality of life

PANCREASE* Capsules deliver

PANCREATIN BP

the full dose of enzyme right to the site of digestion.

PANCREASE* – the only enteric coated microsphere preparation.

- Protected from gastric inactivation
- Improves nutritional status
- Effective in Cystic Fibrosis and Chronic Pancreatic Insufficiency.

PRESCRIBING INFORMATION – PANCREASE* Capsules

Presentation: Hard white gelatin capsules containing enteric coated beads of pancreatin BP. Each capsule has a protease activity of not less than 330 BP Units and amylase activity of not less than 2,900 BP Units and lipase activity of not less than 5,000 BP Units. **Uses:** Exocrine pancreatic enzyme deficiency. **Dosage and administration:** For adults and children 1 or 2 capsules during each meal and one capsule with snacks. To protect the enteric coating the beads should not be crushed or chewed. **Contra-indications, warnings, etc.** Hypersensitivity to pork protein. The safety of Pancrease* during pregnancy has not yet been established. Such use is not recommended. The most frequently reported adverse reactions to Pancrease* Capsules are gastrointestinal in nature. Contact of the beads with food having a pH higher than 5.5 can dissolve the protective enteric shell. **Pharmaceutical precautions:** Keep bottle tightly closed. Store at room temperature in a dry place. Do not refrigerate. **Legal category:** P. **Package Quantities:** Containers of 100 capsules. **Basic NHS Cost:** £15.98 (for 100 capsules). **Product Licence Number:** PL 76/129.

ORTHO Cilag

Further information available from:
Ortho Cilag Pharmaceutical Ltd.,
P.O. Box 79, Saunderton,
High Wycombe, Bucks. HP14 4HJ

Monatsschrift Kinderheilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

135. Band
Heft 7
Juli 1987

Springer-Verlag
Berlin Heidelberg New York London
Paris Tokyo

Vorträge der 82. Tagung der Deutschen Gesellschaft für Kinderheilkunde vom 14. bis 17. September 1986 in Münster

Indexed in Current Contents

Monatsschr Kinderheilkd (1987) 135, 7

Annual subscription: DM 288,- plus postage

THE HEINZ FELLOWSHIPS OF THE BRITISH PAEDIATRIC ASSOCIATION

H. J. Heinz Company Limited generously endows Fellowships in Paediatrics which are administered by the British Paediatric Association.

Two or three Fellowships will be offered each year, the number and type awarded in any one year depending on circumstances and the calibre of applicants available.

The types of Fellowship, which are open to men or women are:

A To enable paediatricans from any part of the Commonwealth overseas to spend up to twelve weeks in the United Kingdom, meeting British Paediatricians and seeing something of their work. Preference will be given to those recently established in an academic career who can arrange their visit to allow attendance at the Annual Meeting of the British Paediatric Association in April 1989.

C To enable paediatricians from the United Kingdom of Registrar, Senior Registrar, or Consultant status, or non-medically qualified members of the Association, in the early years of professional life to make a short working visit (up to three months) to a centre in a developing country, teaching or conducting research so as to benefit both fellow and hosts.

Applications for A Fellowships must be received by the British Paediatric Association not later than 31st December 1987.

Applications for C Fellowships can be accepted by 31st January 1988 or 31st July 1988.

The conditions for the Fellowships and applications forms may be obtained from the British Paediatric Association, 5 St Andrew's Place, Regent's Park, London NW1 4LB.

European Journal of
Pediatrics

Incorporating
ACTA PAEDIATRICA BELGICA

Volume 146 Number 4 July 1987

Subscription information: Volume 146 (6 issues) will appear in 1987. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: Approx. US $ 501.00 including carriage charges. Subscriptions are entered with prepayment only. Orders should be addressed to: Springer-Verlag New York Inc., Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094, USA, Tel. (201) 348-4033, Telex 023125994.

All other countries. Annual subscription rate: DM 996.00 plus carriage charges. Volume price: DM 996.00, single issue price: DM 199.20 plus carriage charges. Airmail delivery on request only. Carriage charges for SAL (Surface Airmail Lifted) to Japan, India, Australia and New Zealand are available on request. Orders can either be placed with your bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33, Tel. (0)30/8207-1, Telex 183319.

Springer International

Published by British Medical Association, Tavistock Square, London WC1H 9JR, and printed in England by The Devonshire Press Ltd., Torquay

CONSIDERING WHAT THEY HAD TO GET RIGHT...



IT'S NO WONDER MORE AND MORE DIABETICS USE

PRESCRIBING INFORMATION
HUMAN MIXTARD® 30/70 (Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (rDNA)). **Presentation.** HUMAN MIXTARD 30/70 is available in 10 ml vials containing 100 iu/ml. To aid identification the metal sealing rings of Human Mixtard vials have three tactile marks. The vials are fitted with tamper-proof caps.
Uses. The treatment of insulin-requiring diabetes.
Dosage and Administration. The dosage of insulin is determined by the requirement according to the needs of the patient. Human Mixtard 30/70 should be re-suspended by inverting the vial several times before being given by s.c. or i.m. injection (it must not be given intravenously).
Use in pregnancy. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters.
Use in the elderly. Insulin may have a more prolonged action due to reduced clearance rates.
Contra-indications, Warnings etc.
Contra-indications. Hypoglycaemia.
Precautions. Patients transferring from other insulins may require a dosage adjustment. Concomitant therapy with thyroxine, corticosteroids, oral contraceptives, diuretics, beta blockers and M.A.O.I.s may affect insulin requirements.
Side and Allergic Effects. Hypoglycaemia. Local reactions, lipodystrophy and hypersensitivity reactions are rarely reported with human insulins.
Pharmaceutical Precautions. Store between 2 - 8°C, protected from sunlight. Insulin which has been frozen should not be used.
Legal Category. P. **Package Quantities.** 10 ml. glass vials.
Basic NHS Price: £8.95.
Product Licence Number. **NORDISK UK** 3132/0037
THE WELLCOME FOUNDATION LTD 0003/0213

Further information is available on request from either:
Nordisk UK, Highview House, Tattenham Crescent, Epsom, Surrey KT18 5QL. Tel. Burgh Heath (07373) 56621.
Wellcome Medical Division, The Wellcome Foundation Ltd., Crewe Hall, Crewe, Cheshire, CW1 4UB. Tel: Crewe (0270) 58315.
®Registered Trade Mark

Nordisk | Wellcome

HUMAN MIXTARD® 30/70

Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (rDNA)

Simple · Convenient · Effective

CONTROL THAT WON'T TIE THEM IN KNOTS